Please contact us for more information or to learn if you are eligible to participate.
To determine whether dapagliflozin 10 mg is superior to placebo, in reducing disease progression, complications, and all-cause mortality in patients hospitalized with COVID-19
Marcel Twahirwa, MD
Luis Cantu Jr.
St. Luke's Hospital of Kansas City
Type of Trial